Fig. 5From: P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signalingImmunohistochemistry and western blot analysis of TLR2 and TLR4 in serous papillary OC. The immunoreactivity for TLR2 was moderate (arrow) in the P-MAPA (b) compared to a weak immunostaining in OC animals (a). While CIS therapy (c) showed a weak immunoreaction for TLR2, the combination of P-MAPA and CIS exhibited variations from weak to moderate (d) (arrows). TLR4 immunoreactivity was intense (arrow) in the P-MAPA (f) compared to weak reaction in the OC animals (e). In addition, the combination of P-MAPA with CIS promoted an intense immunoreaction to TLR4 (h) compared to CIS therapy (g) (arrows). Bar = 20 μm. Negative controls were used. i Expression profile of the TLR2 and TLR4 in extracts of 50 μg proteins pooled from 5 samples per group. j, k Individual blots were used for densitometric analysis of the TLR2 and TLR4 levels following normalization to the β-actin. Data are expressed as the mean ± SD. a P < 0.05 vs. OC; b P < 0.05 vs. CISBack to article page